Hiking the price of a drug before generics appear is a long-enshrined practice, a situation that applies to most of the products singled out by Icer.
Non-US big biopharma stocks led the way in the third quarter, suggesting that those looking for investment gains would do best to search further afield.
An analysis of stock market movers during the period of this year’s Esmo congress gives biotech watchers little cause for happiness.
Parps show more promise in ovarian and prostate cancers, but Kras disappoints. Here's a round up of Vantage's coverage of the 2019 European Society for Medical…
As selpercatinib confirms its activity in thyroid cancer, Eli Lilly gears up to prove the Ret inhibitor’s potential in larger trials.
An analysis of EvaluatePharma data shows that, in a Bristol-Myers Squelgene world, all big pharmas are increasing their reliance on external projects.
Lundbeck needed a deal, but it could struggle against strong competition in migraine.
Sanofi has said goodbye to Lexicon, but after years of failing to keep up with rivals, there is scope for the French drug maker to make more drastic cuts to its diabetes…